Clinical Trials at Duke Comprehensive Cancer Center

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact Bernice Osborne, RN at (919) 684-3780.

Trial Phase Gynecological Cancers - Ovarian cancer and cancers of the female organs
00019289 II GOG-0229I: A Phase II Evaluation of Brivanib (BMS582664, IND #105029), An Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma (BMS Study CA182-029)
00004900 II A Phase II Trial of Avastin in Combination with Docetaxel in Patients with Recurrence of Epithelial Carcinoma of the Ovary/Fallopian Tube/Peritoneum within 12 Months of Platinum Therapy
00007487 III A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery In Platinum-Sensitive, Recurrent Ovarian, Periton
00015753 II GOG 0232C: A Phase II Evaluation of Paclitaxel (TAXOL®, NSC #673089), Carboplatin (PARAPLATIN®, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma
00009570 II Phase II Trial of Topotecan, Cisplatin, and Bevacizumab for Recurrent/Persistent Cervical Cancer
00002859 II A Phase II Evaluation of Abraxane in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
00003671 II GOG0087M: Phase II Evaluation of Trabectedin (Yondelis, R279742, IND #75,111) in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas
00012282 I A Phase I Trial of a SRC Kinase Inhibitor, Dasatinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian, Peritoneal, and Tubal Cancer BMS#CA180-081
00010590 III Phase III Randomized Trial of Induction CT with Gemcitabine and Carboplatin Followed by Elective Paclitaxel Consolidation Vs. Paclitaxel and Carboplatin Followed by Elective Paclitaxel Consolidation in Patients with Primary Epithelial Ovarian, Primary Pe
00006461 II A Pilot Phase II Study Evaluating the Combination of Oxaliplatin and Docetaxel with Bevacizumab as First Line Therapy in Patients with FIGO Stage IB-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma
00013704 II A Randomized, Double-Blind, Placebo Controlled, Multicenter Trial of Abagovomab Maintenance Therapy in Patients with Epithelial Ovarian Cancer After Complete Response to First Line Chemotherapy
00006358 III GOG 0212 Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND#70177), Versus No GOG 0212 Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Perito
00011660 III GOG 0218 Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC #704865, IND #7921) followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and extended Bevacizumab, in
00013247 I A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant (Montanide ISA 51) as Consolidation Following Debulking (Optimal or Suboptimal) and Systemic Chemotherapy for Women with Advanced Stage Ovarian, Tubal, or Peritoneal Cancer
00005403 II GOG 187: Phase II Study of Paclitaxel for Ovarian Stromal Tumors as First-Line or Second-Line Therapy.
00006275 III GOG-0219: Phase III Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage 1B2, IIA, IIB, IIIB and IVA Cervical Carcinoma Limited to the Pelvis
00008478 III GOG 209: Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel/G-CSF VS Carboplatin/Paclitaxel in Patients with Stage III and IV or Recurrent Endometrial Cancer.
00006425 II GOG 130E A Phase II Evaluation of Gemcitabine (NSC #613327) and Docetaxel ( NSC #628503) in the Treatment of Recurrent or Persistent Carinosarcoma of the Uterus
00013409 II GOG 205: Phase II Trial of RT and Weekly Cisplatin CT for the Treatment of Locally-Advanced Squamous Cell Carcinoma of the Vulva.
Duke Comprehensive Cancer Center Accolades